Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Internal Medicine
•
Pulmonology
•
Diffuse Parenchymal Lung Disease
What immunosuppression regimens do clinicians use in patients with progressive RB-ILD despite smoking cessation and prednisone?
Related Questions
In a patient with low titer +anti-SAE antibody and known ILD, but no other clinical features of dermatomyositis, how would you approach further testing or would you treat the patient as dermatomyositis associated ILD?
What are the next steps in management of IPF exacerbation resistant to steroid therapy?
Do you monitor CBCs to assess for drug toxicity in patients on nintedanib?
Would you add abatacept to treat active inflammatory arthritis in a patient with history of RA-ILD who is already taking mycophenolate?
Would you consider adding or switching to pirfenidone for a patient with progressing UIP (based on imaging and PFTs) who is currently on nintedanib?
Would you offer lung SBRT in a patient with Pulmonary Langerhans Cell Histiocytosis (PLCH)?
How do you approach the use of benzodiazepines in patients with chronic medical illnesses that may be susceptible to respiratory compromise (e.g., CHF, COPD, ILD)?
What is your approach to evaluating amiodarone induced interstitial pneumonitis?
How do you approach a patient with sarcoidosis who cannot tolerate steroids and who is developing ILD?
Have you adopted the use of low dose morphine for treatment of cough in patients with IPF?
